Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study

Acta Oto-Laryngologica

Volumn 130, Issue 9, 2010, Pages 1058-1064

  Zhou, Bing ^a   Jiang, Xuejun ^b   Zhai, Lijie ^c   Xiao, Shuifang ^d   Wang, Jiadong ^e   Xiao, Gensheng ^f   Ruan, Biao ^g   Liang, Chuanyu ^h   Ye, Qing ⁱ   Hu, Baohua ^j   Wang, Haibo ^k  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b First Hospital of China Medical University   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^g KUNMING MEDICAL UNIVERSITY   (China)

^h SICHUAN UNIVERSITY   (China)

ⁱ FUJIAN PROVINCIAL HOSPITAL   (China)

^j The People's Hospital of Yuyao   (China)

^k SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

more..

Author keywords

Effectiveness; Safety; Tolerability

Indexed keywords

MOXIFLOXACIN;

ABDOMINAL DISCOMFORT; ACUTE SINUSITIS; ADULT; AGED; ARTICLE; BACTERIAL SINUSITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY NOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; STOMACH DISCOMFORT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; QUINOLINES; RHINITIS; SINUSITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956039709     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016481003629036     Document Type: Article

References (7)

1. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-2002. Vital Health Stat 2006;13:1-66.
2. Anon JB, Jacobs MR, Poole MD, Ambrose PG, Benninger MS, Hadley JA, et al. Sinus And Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130 (Suppl 1):1-45.
3. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-246
4. Ariza H, Rojas R, Johnson P, Gower R, Benson A, Herrington J, et al. Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis. BMC Ear Nose Throat Disord 2006;6:8.
5. Fairbanks DNF. Pocket guide to antimicrobial therapy in otolaryngology, head and neck surgery, 13th edition. American Academy of Otolaryngology, Head and Neck Surgery Foundation.
6. Johnson P, Cihon C, Herrington J, Choudhri S. Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis. Clin Ther 2004;26:224-231
7. Keating KN, Friedman HS, Perfetto EM. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges. Curr Med Res Opin 2006;22:327-333